Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment. Jazz Pharmaceuticals markets multiple ...

Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

Explore the hidden dangers of excessive yawning and sleep deprivation. Learn how insufficient sleep can affect your health, behavior, and cognitive functioning, and discover expert recommendations to ...